Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers April 22, 2018
Pharmacy Choice - Pharmacy News - April 22, 2018

Pharmacy News

Today's Pharmaceutical and Pharmacy News
Daily News Topic:

FDA News
4/21/18 - AZ`s Tagrisso gets FDA nod in first-line EGFR-mutated lung cancer [Tehran Times (Iran)]
AstraZeneca has announced that its epidermal growth factor receptor tyrosine kinase inhibitor Tagrisso has received approval from the FDA for the first-line treatment of metastatic non-small cell lung cancer in patients whose tumours have EGFR mutations, specifically exon 19 deletions or exon 21 L858R mutations, as detected by an FDA- approved test
4/21/18 - AZs Tagrisso approved for untreated lung cancer in US [Tehran Times (Iran)]
AstraZenecas Tagrisso looks set to gain further traction after the FDA approved it in first-line treatment for lung cancer patients with a certain mutation. Dr Suresh Ramalingam, principal investigator of the FLAURA trial, from Winship Cancer Institute of Emory University, Atlanta, said: The approval of osimertinib in the first-line setting represe
4/21/18 - FDA approves first contact lens that gets darker in sunlight [Tehran Times (Iran)]
The U.S. Food and Drug Administration has signed off on the first ever transition contact lenses, which will get darker when the wearer is out in sunlight. The Acuvue Oasys transition contact lenses are from Johnson& Johnson Vision Care, Inc.. Johnson& Johnson says the new lenses will hit the market during the "first half of 2019.".
4/21/18 - FDA approves first therapy for rare inherited form of rickets, x-linked hypophosphatemia [Sudan Tribune]
The U.S Food and Drug Administration has approved Crysvita, the first drug approved to treat adults and children ages 1 year and older with x-linked hypophosphatemia, a rare, inherited form of rickets. XLH differs from other forms of rickets in that vitamin D therapy is not effective, stated Dr Julie Beitz, director of the Office of Drug Evaluation
4/21/18 - FDA Approves Fostamatinib for ITP After Insufficient Response to Previous Treatment [T-break Tech (Middle East)]
Fostamatinib disodium hexahydrate, a kinase inhibitor, was granted FDA approval for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had insufficient response to a previous treatment. Recommended dose is 100 mg orally twice daily. If a platelet count of at least 50109/ L is not achieved in 1 month af
4/21/18 - FDA Approves Osimertinib for Treatment of Non-Small Cell Lung Cancer [Tehran Times (Iran)]
Officials with the FDA have approved osimertinib for the first-line treatment of patients with metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor mutations, according to a press release. Osimertinib is already approved in the United States for the second-line treatment of patients with metastatic EGFRm NSCLC,..

Chain Drug Review
Chain Drug Review Magazine Chain Drug Review, established in 1978 and published 21 times a year, is recognized as the premier news publication serving the entire chain drug store industry.
Featured Article from Chain Drug Review:
AWP suit settlement appealed
The National Association of Chain Drug Stores has appealed a U.S. District Court’s approval of settlements in the First DataBank Inc. and Medi-Span Inc. lawsuit. »read more

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
Pharmacy Spanish
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement